ISLATRAVIR DISTRIBUTION IN MUCOSAL TISSUES, PBMC, & PLASMA AFTER MONTHLY ORAL DOSING
Islatravir (ISL), a novel nucleoside analogue with multiple mechanisms of action, has the potential to be an important new agent for HIV-1 pre-exposure prophylaxis (PrEP) due to its potent HIV-1 antiviral activity and long intracellular half-life. We evaluated ISL PK in blood and mucosal tissues (rectal, vaginal, and cervical) after monthly (QM) oral dosing; evaluation…